1-20 of 58
S Verma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5239: Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation

Yonina R. Murciano-Goroff, Srinivasaraghavan Kannan, Jason C. Chang, Ryma Benayed, Ilya Blokhin, Natasha Rekhtman, Ann Elizabeth Sisk, Jaime Gibson, Lia Judka, Lauren Kaplanis, Madeline Merrill, Erica Sgroe, Chandra S. Verma, Alexander Drilon, Emiliano Cocco
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5239.
https://doi.org/10.1158/1538-7445.AM2022-5239
Published: 15 June 2022
View article titled, Abstract 5239: Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation
Journal Articles

Abstract 5358: Involvement of solute carrier transporters SLC25A17 and SLC27A6 in metabolic reprograming of castration-resistant prostate cancer

Prem P. Kushwaha, Shiv S. Verma, Eswar Shankar, Spencer Lin, Sanjay Gupta
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5358.
https://doi.org/10.1158/1538-7445.AM2022-5358
Published: 15 June 2022
View article titled, Abstract 5358: Involvement of solute carrier transporters SLC25A17 and SLC27A6 in metabolic reprograming of castration-resistant prostate cancer
Journal Articles

Abstract 1070: Dual inhibition of AR and β-catenin induces cell death in abiraterone-resistant prostate cancer

Ibrahim M. Atawia, Prem P. Kushwaha, Shiv S. Verma, Spencer Lin, Eswar Shankar, Osama Abdel-Gawad, Sanjay Gupta
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1070.
https://doi.org/10.1158/1538-7445.AM2022-1070
Published: 15 June 2022
View article titled, Abstract 1070: Dual inhibition of AR and β-catenin induces cell death in abiraterone-resistant prostate cancer
Journal Articles

Abstract 1467: Metabolic reprogramming fuels prostate cancer cells towards enzalutamide resistance

Shiv S. Verma, Eswar Shankar, Rajnee Kanwal, Ricky Chan, Sanjay Gupta
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1467.
https://doi.org/10.1158/1538-7445.AM2020-1467
Published: 15 August 2020
View article titled, Abstract 1467: Metabolic reprogramming fuels prostate cancer cells towards enzalutamide resistance
Journal Articles

Abstract 3439: FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer

Amaia Arruabarrena-Aristorena, Jesper LV Maag, Srushti Kittane, Yanyan Cai, Jane Park, Pedram Razavi, Lorenzo Ferrando, Pier Selenica, Wouter R. Karthaus, Srinivasaraghavan Kannan, Emiliano Cocco, Sik Y. Ho, Daisylyn Senna Tan, Mirna Sallaku, Charles L. Sawyers, Jorge S. Reis-Fihlo, Chandra S. Verma, Ralf Jauch, Richard Koche, José Baselga, Eneda Toska, Maurizio Scaltriti
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3439.
https://doi.org/10.1158/1538-7445.AM2020-3439
Published: 15 August 2020
View article titled, Abstract 3439: FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer
Journal Articles

Abstract OT3-04-02: Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

HL McArthur, JHS Leal, C DiLauro Abaya, R Basho, H Coleman, S Shiao, S Knott, M Tighiouart, F Dadmanesh, A Giuliano, S Verma
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT3-04-02.
https://doi.org/10.1158/1538-7445.SABCS18-OT3-04-02
Published: 15 February 2019
View article titled, Abstract OT3-04-02: Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial
Journal Articles

Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study

S Verma, J Shahidi, C Lee, K Wang, J Cortes
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT2-07-03.
https://doi.org/10.1158/1538-7445.SABCS18-OT2-07-03
Published: 15 February 2019
View article titled, Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study
Journal Articles

Abstract P2-08-13: Survival in women with de novo metastatic breast cancer: Comparison of real-world evidence from publicly-funded Canadian province and the United States by insurance status

EN Kornaga, AR Matutino, AA Pereira, S Verma, S Lupichuk
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-08-13.
https://doi.org/10.1158/1538-7445.SABCS18-P2-08-13
Published: 15 February 2019
View article titled, Abstract P2-08-13: Survival in women with de novo metastatic breast cancer: Comparison of real-world evidence from publicly-funded Canadian province and the United States by insurance status
Journal Articles

Abstract P6-16-09: What research questions matters most to patients? Final results of the metastatic breast cancer priority setting partnership

NA Nixon, C Simmons, J Lemieux, S Verma
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-16-09.
https://doi.org/10.1158/1538-7445.SABCS18-P6-16-09
Published: 15 February 2019
View article titled, Abstract P6-16-09: What research questions matters most to patients? Final results of the metastatic breast cancer priority setting partnership
Journal Articles

Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials

JT Beck, P Neven, FJ Esteva, A Bardia, N Harbeck, S Hurvitz, J O'Shaughnessy, S Verma, B Lanoue, J Alam, O Kong, D Chandiwana, S Chia
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-18-14.
https://doi.org/10.1158/1538-7445.SABCS18-P6-18-14
Published: 15 February 2019
View article titled, Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials
Journal Articles

Abstract P2-03-12: Incidence and implications for hormone receptor status change pre- and post- neoadjuvant chemotherapy for locally advanced breast cancer: A retrospective single-center cohort study

O Aseyev, L Simmonds, M Gertler, S Verma
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P2-03-12.
https://doi.org/10.1158/1538-7445.SABCS17-P2-03-12
Published: 15 February 2018
View article titled, Abstract P2-03-12: Incidence and implications for hormone receptor status change pre- and post- neoadjuvant chemotherapy for locally advanced breast cancer: A retrospective single-center cohort study
Journal Articles

Abstract P5-19-07: Defining priorities for research: Interim results of the Canadian metastatic breast cancer priority setting partnership

N Nixon, C Simmons, J Lemieux, S Verma
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-19-07.
https://doi.org/10.1158/1538-7445.SABCS17-P5-19-07
Published: 15 February 2018
View article titled, Abstract P5-19-07: Defining priorities for research: Interim results of the Canadian metastatic breast cancer priority setting partnership
Journal Articles

Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)

D Miles, F André, J Gligorov, S Verma, B Xu, D Cameron, CH Barrios, A Schneeweiss, V Easton, Y Ghazi, J O'Shaughnessy
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): OT1-01-01.
https://doi.org/10.1158/1538-7445.SABCS17-OT1-01-01
Published: 15 February 2018
View article titled, Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)
Journal Articles

Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors

J Baselga, J Cortés, M De Laurentiis, S Dent, V Diéras, N Harbeck, J Hsu, H Jin, F Schimmoller, TR Wilson, Y-H Im, W Jacot, IE Krop, S Verma
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): OT2-01-01.
https://doi.org/10.1158/1538-7445.SABCS16-OT2-01-01
Published: 15 February 2017
View article titled, Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with <em>PIK3CA-</em>mutant tumors
Journal Articles

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

HA Burris, A Chan, M Campone, KL Blackwell, EP Winer, W Janni, S Verma, O Burdaeva, E Alba, AM Favret, S Mondal, M Miller, C Germa, S Hirawat, YS Yap
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-22-16.
https://doi.org/10.1158/1538-7445.SABCS16-P4-22-16
Published: 15 February 2017
View article titled, Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial
Journal Articles

Abstract P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies

HS Rugo, NC Turner, RS Finn, AA Joy, S Verma, N Harbeck, S Moulder, N Masuda, Y-H Im, K Zhang, S Kim, W Sun, P Schnell, C Huang-Bartlett, D Slamon
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-22-03.
https://doi.org/10.1158/1538-7445.SABCS16-P4-22-03
Published: 15 February 2017
View article titled, Abstract P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies
Journal Articles

Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

NC Turner, F André, M Cristofanilli, S Verma, H Iwata, S Loi, N Harbeck, J Ro, M Colleoni, K Zhang, C Huang Bartlett, C Giorgetti, D Slamon
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-22-06.
https://doi.org/10.1158/1538-7445.SABCS16-P4-22-06
Published: 15 February 2017
View article titled, Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3
Journal Articles

Abstract P3-12-01: Value-based approach to treatment of HER2-positive breast cancer: Examining the evidence

NA Nixon, M Hannouf, S Verma
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P3-12-01.
https://doi.org/10.1158/1538-7445.SABCS16-P3-12-01
Published: 15 February 2017
View article titled, Abstract P3-12-01: Value-based approach to treatment of HER2-positive breast cancer: Examining the evidence
Journal Articles

Abstract P2-06-09: Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment

O Aseyev, L Simmonds, M Gertler, S Dent, S Verma
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P2-06-09.
https://doi.org/10.1158/1538-7445.SABCS16-P2-06-09
Published: 15 February 2017
View article titled, Abstract P2-06-09: Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment
Journal Articles

Abstract P4-14-09: Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience

RB Mukku, S Verma, J Liu, R Steingart, C Hudis, AF Yu, C Dang
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P4-14-09.
https://doi.org/10.1158/1538-7445.SABCS15-P4-14-09
Published: 15 February 2016
View article titled, Abstract P4-14-09: Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience